

---

## CORRIGENDUM

### Knocking down barriers: advances in siRNA delivery

Kathryn A. Whitehead, Robert Langer & Daniel G. Anderson

*Nature Reviews Drug Discovery* **8**, 129–138 (2009) | doi:10.1038/nrd2742

On page 136 in Table 3, the clinical trial for acute renal failure has been attributed to Quark/Pfizer when it should be attributed to Quark alone. In addition, the authors would like to clarify that, following a Phase I/II trial in patients with wet age-related macular degeneration, the siRNA drug candidate PF-4523655 (RTP801i-14) is now being studied in a Phase II trial for diabetic macular oedema conducted by Pfizer in collaboration with Quark.